Targeting Akt3 signaling in triple-negative breast cancer

Research output: Journal Publications and Reviews (RGC: 21, 22, 62)21_Publication in refereed journalpeer-review

80 Scopus Citations
View graph of relations

Author(s)

  • Taku Yoshida
  • Andriy Marusyk
  • Andrew H. Beck
  • Kornelia Polyak
  • Alex Toker

Detail(s)

Original languageEnglish
Pages (from-to)964-973
Journal / PublicationCancer Research
Volume74
Issue number3
Online published12 Dec 2013
Publication statusPublished - 1 Feb 2014
Externally publishedYes

Abstract

Triple-negative breast cancer (TNBC) is currently the only major breast tumor subtype without effective targeted therapy and, as a consequence, in general has a poor outcome. To identify new therapeutic targets in TNBC, we performed a short hairpin RNA (shRNA) screen for protein kinases commonly amplified and overexpressed in breast cancer. Using this approach, we identified AKT3 as a gene preferentially required for the growth of TNBCs. Downregulation of Akt3 significantly inhibits the growth of TNBC lines in threedimensional (3D) spheroid cultures and in mouse xenograft models, whereas loss of Akt1 or Akt2 have more modest effects. Akt3 silencing markedly upregulates the p27 cell-cycle inhibitor and this is critical for the ability of Akt3 to inhibit spheroid growth. In contrast with Akt1, Akt3 silencing results in only a minor enhancement of migration and does not promote invasion. Depletion of Akt3 in TNBC sensitizes cells to the pan-Akt inhibitor GSK690693. These results imply that Akt3 has a specific function in TNBCs; thus, its therapeutic targeting may provide a new treatment option for this tumor subtype. © 2013 AACR.

Citation Format(s)

Targeting Akt3 signaling in triple-negative breast cancer. / Chin, Y. Rebecca; Yoshida, Taku; Marusyk, Andriy; Beck, Andrew H.; Polyak, Kornelia; Toker, Alex.

In: Cancer Research, Vol. 74, No. 3, 01.02.2014, p. 964-973.

Research output: Journal Publications and Reviews (RGC: 21, 22, 62)21_Publication in refereed journalpeer-review